alunacedase alfa   Click here for help

GtoPdb Ligand ID: 11320

Synonyms: APN01 | GSK-2586881 | GSK2586881 | rhsACE2
Compound class: Peptide
Comment: Alunacedase alfa (APN01; Aperion Biologics) is a recombinant version of human ACE2 that is intended to act as a decoy (soluble trap) for the SARS-CoV-2 spike protein [1,4-5], than can neutralise the virus [4]. Recombinant ACE2 was originally proposed as a mechanism to combat acute respiratory distress syndrome (ARDS) caused by the SARS-CoV virus [2], which like SARS-CoV-2 uses ACE2 to infect host cells. Structurally APN01 is a glycosylated dimer of peptide chains that form the extracellular domain of the enzyme. It is produced in Chinese hamster ovary (CHO) cells, and it contains several intra-subunit disulphide bridges.
No information available.
Summary of Clinical Use Click here for help
Alunacedase alfa (APN01) is well-advanced as a drug candidate for the treatment of COVID-19.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04287686 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 N/A Interventional The First Affiliated Hospital of Guangzhou Medical University
NCT00886353 Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) Phase 1 Interventional Apeiron Biologics
NCT04335136 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 Phase 2 Interventional Apeiron Biologics
NCT01597635 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury Phase 2 Interventional GlaxoSmithKline 3